Amerisource Health Services LLC: Drug Recall

Recall Details

Recall Number

D-0757-2023

Classification

Class II

Product Type

Drug

Recalling Firm

Amerisource Health Services LLC

Status

Terminated

Date Initiated

03/17/2023

Location

Columbus, OH, United States

Voluntary/Mandated

Voluntary: Firm initiated

Product Quantity

63,335 bottles

Reason for Recall

CGMP Deviations: recalling drug products following an FDA inspection.

Product Description

Glimepiride Tablets, USP, 1 mg, RX, Packaged as a)100-count bottle, NDC# 68001-177-00; b) 500-count bottle, NDC# 68001-177-03; Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. INDIA. For BluePoint Laboratories

Distribution Pattern

Nationwide USA

Other Recalls by Amerisource Health Services LLC

• Class II: Risk 10/16/2025
  Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
• Class II: Risk 10/16/2025
  Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
• Class II: Risk 10/16/2025
  Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
• Class II: Risk 10/09/2025
  CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.
• Class II: Risk 09/15/2025
  Failed Dissolution Specifications.

View all recalls by Amerisource Health Services LLC →